Abstract
Idiopathic pulmonary fibrosis (IPF), or usual interstitial pneumonitis (UIP) is one of the most common causes of pulmonary fibrosis. It is characterized by progressive fibrosis of both lungs. The diagnosis is usually made on the basis of high resolution CT scan of chest or open lung biopsy. Treatment for UIP has been mainly empirical. Besides lung transplant, no clear-cut medical therapy has emerged. In 2010 European union approved pirfenidone. The approval by this drug lagged in USA. On October 15th 2014, Food and Drug Administration (FDA) approved Nintedanib and Pirfenidone for patient use in United States of America. We present a brief commentary on the basic disease process and the new emerging therapies.
Keywords: IPF, nintedanib, pirfenidone, UIP.
Current Respiratory Medicine Reviews
Title:Emerging Approved Treatments for Idiopathic Pulmonary Fibrosis: Some Hope for Patients?
Volume: 10 Issue: 4
Author(s): Shawn Johnson and Salim Surani
Affiliation:
Keywords: IPF, nintedanib, pirfenidone, UIP.
Abstract: Idiopathic pulmonary fibrosis (IPF), or usual interstitial pneumonitis (UIP) is one of the most common causes of pulmonary fibrosis. It is characterized by progressive fibrosis of both lungs. The diagnosis is usually made on the basis of high resolution CT scan of chest or open lung biopsy. Treatment for UIP has been mainly empirical. Besides lung transplant, no clear-cut medical therapy has emerged. In 2010 European union approved pirfenidone. The approval by this drug lagged in USA. On October 15th 2014, Food and Drug Administration (FDA) approved Nintedanib and Pirfenidone for patient use in United States of America. We present a brief commentary on the basic disease process and the new emerging therapies.
Export Options
About this article
Cite this article as:
Johnson Shawn and Surani Salim, Emerging Approved Treatments for Idiopathic Pulmonary Fibrosis: Some Hope for Patients?, Current Respiratory Medicine Reviews 2014; 10 (4) . https://dx.doi.org/10.2174/1573398X11666141208233106
DOI https://dx.doi.org/10.2174/1573398X11666141208233106 |
Print ISSN 1573-398X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6387 |
Call for Papers in Thematic Issues
Exposure to PM2.5 components is associated with respiratory diseases
Through continuous research on the relationship between risk factors and health, it has been found that air pollution, especially atmospheric particulate matter pollution, has become one of the main sources of global disease burden. From 1990 to 2022, the concentration of atmospheric particulate matter pollution has increased by more than ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Medico-Legal Issues with CTG Interpretation
Current Women`s Health Reviews Targeting the Toll-System in Cardiovascular Sciences
Recent Patents on Inflammation & Allergy Drug Discovery Targeting CD4 to Disrupt Signaling Through Membrane Rafts: Towards a Raft-Based Therapeutics
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Periodontitis and Atherosclerosis, a Causal Relationship?
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Characterization, ACE Inhibitory and Antioxidative Properties of Peptide Fractions Obtained from White Shrimp (<i>Litopenaeus vannamei</i>)
Current Bioactive Compounds Editorial [Hot Topic: ADAMs: Targets for Drug Discovery (Executive Editor: Marcia L. Moss)]
Current Pharmaceutical Design Liver Disease in Diabetes Mellitus: Potential Therapeutic Value of Vitamin E-Silybin Phytosomal Complex
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Active Nano-targeting of Macrophages
Current Pharmaceutical Design Recent Advances in the Development of MMPIs and APNIs Based on the Pyrrolidine Platforms
Mini-Reviews in Medicinal Chemistry Identification of New Pancreatic Beta Cell Targets for In Vivo Imaging by a Systems Biology Approach
Current Pharmaceutical Design A Comparison of Non-Human Primate Cytochrome P450 2D Members and the Implication in Drug Discovery
Current Drug Metabolism Advanced Therapies For End-Stage Heart Failure
Current Cardiology Reviews Seeing Genes at Work in the Living Brain with Non-Invasive Molecular Imaging
Current Gene Therapy Mouse Models of Autoimmune Diseases - Autoimmune Myocarditis
Current Pharmaceutical Design Invariant Natural Killer T Cell-Based Therapy of Autoimmune Diseases
Current Immunology Reviews (Discontinued) Dyspnea in Cancer Patients: A Well-Known and Neglected Symptom
Reviews on Recent Clinical Trials Natural Agents Modulating ACE-2: A Review of Compounds with Potential against SARS-CoV-2 Infections
Current Pharmaceutical Design System Bioinformatic Approach Through Molecular Docking, Network Pharmacology and Microarray Data Analysis to Determine the Molecular Mechanism Underlying the Effects of Rehmanniae Radix Praeparata on Cardiovascular Diseases
Current Protein & Peptide Science FGF21 and its Relationship with Inflammatory and Metabolic Parameters in HIV Patients after Antiretroviral Treatment
Current HIV Research Mitochondrial Toxicity in HAART: An Overview of In Vitro Evidence
Current Pharmaceutical Design